2026. Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605). SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s746. DOI:https://doi.org/10.25251/nq0ynj58.